As of Friday close, BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) stock was up $0.19, moving up 2.65 percent to $7.35. The average number of shares traded per day over the past five days has been 2,939,900 shares. 2 times new highs have been achieved over the past 5 days, with a $0.50 gain in that time frame. In the last twenty days, the average volume was 2,468,595, while in the previous 50 days, it was 2,605,806.
Since last month, BCRX stock rose 3.23%. Shares of the company fell to $6.68 on 09/13/23, the lowest level in the past month. A 52-week high of $14.50 was reached on 01/06/23 after having rallying from a 52-week low of $6.62. Since the beginning of this year, BCRX’s stock price has dropped by -35.98% or -$4.13, and marked a new high 3 times. However, the stock has declined by -49.31% since its 52-week high.
BCRX stock investors should be aware that BioCryst Pharmaceuticals Inc. (BCRX) stock had its last reported insider trading activity 100 days ago on Jun 15. SANDERS MACHELLE, the Director of the company, disposed of 4,000 shares for $7.98 on Jun 15. It resulted in a $31,920 divestment by the insider. Hutson Nancy J sold 12,866 shares at an average price of $8.04 on Jun 14. The insider now owns 81,818 shares following the transaction. On Apr 03, Chief R&D Officer Thackray Helen M. sold 7,000 shares at $8.29 apiece. The transaction was valued at $58,030.
Financial Health
In the three months ended June 29, BioCryst Pharmaceuticals Inc.’s quick ratio stood at 5.20, while its current ratio was 5.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 97.40% percent. In the year ended June 29, EBITDA margin amounted to -54.28%, whereas operating margins totaled -46.30%. Based on annual data, BCRX earned $264.42 million in gross profit and brought in $270.83 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -34.50%. Return on equity (ROE) for the past 12 months was 77.40%.
In BioCryst Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $293.18 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BCRX’s revenue rose 20.56% to $68.78 million during the quarter, while net income inched up to $82.49 million. While analysts expected BioCryst Pharmaceuticals Inc. to report -$0.23 quarterly earnings, the actual figure was -$0.4 per share, beating the consensus estimate by -73.90%. During the quarter, the company generated -$23.13 million in EBITDA. The liabilities of BioCryst Pharmaceuticals Inc. were 918.6 million at the end of its most recent quarter ended June 29, and its total debt was $827.63 million. The value of shareholders’ equity is $189.49 million.
Technical Picture
This quick technical analysis looks at BioCryst Pharmaceuticals Inc.’s (BCRX) price momentum. With a historical volatility rate of 64.80%, the RSI 9-day stood at 56.05% on 22 September.
With respect to its five-day moving average, the current BioCryst Pharmaceuticals Inc. price is up by +7.30% percent or $0.50. At present, BCRX shares trade +1.52% above its 20-day simple moving average and -2.13% percent below its 100-day simple moving average.
Stochastic coefficient K was 46.20% and Stochastic coefficient D was 57.87%, while ATR was 0.36. Given the Stochastic reading of 58.78% for the 14-day period, the RSI (14) reading has been calculated as 54.00%. As of today, the MACD Oscillator reading stands at 0.05, while the 14-day reading stands at 0.12.
Analyst Ratings
RBC Capital Mkts upgraded its rating on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to an Outperform in a note to investors on September 18, 2023. The analysts firm previously had a Sector perform rating on the stock.BioCryst Pharmaceuticals Inc. (BCRX) has been rated Buy by analysts. According to 0 brokerage firms, BCRX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate BioCryst Pharmaceuticals Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $11.50, the current consensus forecast for the stock is $8.00 – $30.00. Based on these forecasts, analysts predict BioCryst Pharmaceuticals Inc. (BCRX) will achieve an average price target of $15.20.
